SECURE-AD registry and Patient survey update

SECURE-AD is a global registry of patients with atopic dermatitis who experience a COVID-19 episode:

SECURE-AD registry

We encourage clinicians worldwide to report all cases of COVID-19 in their atopic eczema patients, treated with or without systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening). There are currently 238 cases reported in the SECURE-AD Registry.

Data entry takes only around 5 minutes and is completely anonymous, and we will include anybody who uploads a case as a co-author under the SECURE-AD Study Group. Please continue to enter your cases at this critical time – before the window of opportunity to gather this data has passed.

SECURE-AD Patient Survey

The SECURE-AD Patient Survey allows patients with atopic eczema who have developed COVID-19 to report their experience. please encourage your patients with atopic dermatitis with suspected or confirmed COVID-19 to complete the SECURE-AD Patient Survey. To date 529 patients registered themselves, of whom 187 contracted COVID-19.

How can you help?

The SECURE-AD team would be very grateful if you could continue to use your local and national networks to raise awareness of both registries by emailing your contacts and posting about them on social media (please follow and tag them @AD_secure and use the hashtag #AD_secure).

Both registries are available in 15 languages (Afrikaans, Arabic, Chinese simplified, Chinese traditional, Dutch, English, French, German, Hebrew, Indonesian, Italian, Japanese, Portuguese, Russian and Spanish).

You can also share the attached communication with your patients suffering from atopic dermatitis.

Many thanks for your support.

With best wishes,
Carsten FLOHR, UK